Nocion Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $62M
Overview
A biotech creating non-opioid, peripherally-acting drugs for cough, chronic itch, and neuropathic pain conditions.
NeuroscienceImmunology
Technology Platform
A platform for discovering small molecule 'nociceptor inhibitors' that selectively block specific ion channels on peripheral sensory neurons to treat cough, itch, and pain.
Funding History
1Total raised:$62M
Series B$62M
Opportunities
Its lead program in refractory chronic cough addresses a large patient population with limited options and could be a first-in-class therapy.
Risk Factors
Clinical development risks remain, including potential for taste disturbance (ageusia/dysgeusia) as a class effect for P2X3 antagonists and demonstrating sufficient efficacy over placebo.
Competitive Landscape
A competitive leader in the targeted chronic cough space, facing competition from large pharma and other biotechs developing P2X3 antagonists and other mechanisms.